529 related articles for article (PubMed ID: 33595889)
1. Adjuvant immunotherapy for melanoma.
Thomas D; Bello DM
J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
4. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
Fukumoto T; Horita N
Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
[No Abstract] [Full Text] [Related]
5. [To outwit melanoma with its own tricks].
Bischoff A
MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
[No Abstract] [Full Text] [Related]
6. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
Bhave P; Pallan L; Long GV; Menzies AM; Atkinson V; Cohen JV; Sullivan RJ; Chiarion-Sileni V; Nyakas M; Kahler K; Hauschild A; Plummer R; Trojaniello C; Ascierto PA; Zimmer L; Schadendorf D; Allayous C; Lebbe C; Maurichi A; Santinami M; Roy S; Robert C; Lesimple T; Patel S; Versluis JM; Blank CU; Khattak A; Van der Westhuizen A; Carlino MS; Shackleton M; Haydon A
Br J Cancer; 2021 Feb; 124(3):574-580. PubMed ID: 33087895
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
8. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
Luke JJ; Ascierto PA; Carlino MS; Gershenwald JE; Grob JJ; Hauschild A; Kirkwood JM; Long GV; Mohr P; Robert C; Ross M; Scolyer RA; Yoon CH; Poklepovic A; Rutkowski P; Anderson JR; Ahsan S; Ibrahim N; M Eggermont AM
Future Oncol; 2020 Jan; 16(3):4429-4438. PubMed ID: 31870188
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy of melanomas].
Zimmer L; Vaubel J; Schadendorf D
Hautarzt; 2012 Dec; 63(12):952-8. PubMed ID: 23097082
[TBL] [Abstract][Full Text] [Related]
10. The role of adjuvant therapy in melanoma management.
Barth A; Morton DL
Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
[TBL] [Abstract][Full Text] [Related]
11. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
[TBL] [Abstract][Full Text] [Related]
12. Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises.
Bhave P; Haydon A
Australas J Dermatol; 2020 Aug; 61(3):203-209. PubMed ID: 32403192
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy of cutaneous malignant melanoma: a critical review.
Koh HK; Sober AJ; Harmon DC; Lew RA; Carey RW
Med Pediatr Oncol; 1985; 13(5):244-60. PubMed ID: 3897817
[TBL] [Abstract][Full Text] [Related]
14. [Drug clinics. How I treat cutaneous melanoma].
Piérard-Franchimont C; Piérard GE
Rev Med Liege; 1998 Jan; 53(1):4-6. PubMed ID: 9555173
[TBL] [Abstract][Full Text] [Related]
15. Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials.
Patel A; Skitzki J
J Surg Oncol; 2022 Jan; 125(1):38-45. PubMed ID: 34897704
[TBL] [Abstract][Full Text] [Related]
16. Do Not Forget About the Importance of Loco-Regional Therapy in Melanoma Management.
Wuthrick EJ; Chablani P
Semin Radiat Oncol; 2019 Apr; 29(2):166-170. PubMed ID: 30827455
[TBL] [Abstract][Full Text] [Related]
17. Medical management of melanoma.
Brown CK; Kirkwood JM
Surg Clin North Am; 2003 Apr; 83(2):283-322, viii. PubMed ID: 12744611
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.
Ralli M; Botticelli A; Visconti IC; Angeletti D; Fiore M; Marchetti P; Lambiase A; de Vincentiis M; Greco A
J Immunol Res; 2020; 2020():9235638. PubMed ID: 32671117
[TBL] [Abstract][Full Text] [Related]
19. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eggermont AMM; Dummer R
Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
[TBL] [Abstract][Full Text] [Related]
20. Melanoma: is immunotherapy of benefit?
Faries MB; Morton DL
Adv Surg; 2003; 37():139-69. PubMed ID: 12953631
[No Abstract] [Full Text] [Related]
[Next] [New Search]